Figure S1. Tumor cells are positive for cytokeratin 20. Magnification, x100; scale bar, 200 μ m.



Figure S2. Tumor cells are positive for CDX2. Magnification, x100; scale bar, 200 μ m.



Figure S3. Tumor cells are positive for Villin. Magnification, x40; scale bar, 625 μ m.



Figure S4. Tumor cells are membrane positive for β -catenin. Magnification, x100; scale bar, 200 μ m.



Figure S5. Tumor cells are positive for wild-type p53. Magnification, x100; scale bar, 200 μ m.




Figure S6. Tumor cells are positive for special AT-rich sequence-binding protein 2. Magnification, x100; scale bar, 200 μ m.



Figure S7. Tumor cells are positive for DNA mismatch repair protein MLH1. Magnification, x100; scale bar, 200 μ m.




Figure S8. Tumor cells are positive for MutS homolog 2. Magnification, x100; scale bar, 200 μ m.




Figure S9. Tumor cells are positive for MutS Homolog 6. Magnification, x100; scale bar, 200 μ m.




Figure S10. Tumor cells are positive for PMS1 homolog 2, mismatch repair system component. Magnification, x100; scale bar, $200 \,\mu$ m.



Figure S11. Tumor cells are negative for cytokeratin 7. Magnification, x40; scale bar, $625 \,\mu$ m.




Figure S12. Tumor cells are negative for GATA-3. Magnification, x100; scale bar, 200 μ m.




Figure S13. Tumor cells are negative for Spalt like transcription factor 4. Magnification, x40; scale bar, $625 \,\mu$ m.




Figure S14. Tumor cells are negative for prostate-specific antigen. Magnification, x100; scale bar, 200 μ m.




Figure S15. Tumor cells are negative for α -methylacyl-CoA racemase. Magnification, x40; scale bar, 625 μ m.




Figure S16. Tumor cells are positive for Ki-67. Magnification, x100; scale bar, 200 μ m.

